drugset / Trial / NCT02191813

Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers

NCT02191813 ↗

Phase 2 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to detect the efficacy of Seresis® in reducing the damage produced on the skin by Matrix-metalloproteinases (MMP) and by oxidative stress (marker: heme oxygenase-1 expression) activated by UV radiation

Timeline

Start
2000-03
Primary completion
2000-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Seresis® Unknown — —

Indications

No indication recorded.